The Sundia Board of Directors is responsible for the direction, strategy, organization and administration of the Company. The Board comprises 7 members and is chaired by Ms. Cathy Yen.
Chairman, Ms. Yen has served as a member of our board since 2007. Ms. Yen is a general partner of Asiavest Partners, an investment and venture capital management company which she joined in 2000. Currently, she also sits on the board of a number of private companies with industries across semiconductor, media and consumer products. Prior to joining Asiavest, Ms. Yen has been with Global financial Services, a Lehman Brothers joint venture in Taiwan. Ms. Yen brings to Sundia over 20 years of experience in corporate finance, investment banking, strategy planning and venture capital. Ms. Yen graduated in 1987 with a bachelor degree from National Taiwan University, Taiwan, China and in 1990 with a Master of Business Administration from the same school.
Chen Chen, Ph.D.
CEO, Dr. Chen has a Ph.D. in Organic
Chemistry from the Shanghai Institute of Organic Chemistry, China. He did a
post-doc at Texas A&M University with Nobel Laureate, Professor Sir Derek
H. R. Barton, and a post-doc at the University of Illinois, Chicago. Dr. Chen
spent 15 years at Neurocrine as Scientist to Senior Director of Medicinal
Chemistry on multiple drug discovery projects, including the discovery of
NBI-42902, elagolix, and NBI-30775 (R121919). He has published nearly 130
scientific papers in peer-reviewed journals and is the co-holder of over 25 US
Suyang joined the IDG Capital team in 1994.
His background combines extensive expertise in technology and international
finance with in-depth ties to China’s entrepreneurial community. Suyang
successfully launched a series of high-tech projects in the areas of
electronics, telecommunications and software in recent years. He has been
the central programming coordination manager of Shanghai Bell, deputy
director of Shanghai factory 520 of Minister of Post & Telecommunication,
and General Manager of Hainan Vantone Group Shanghai Company. Suyang earned
his bachelor degree in Electronics Engineering from Shanghai University in
1992. He pursued further studies in business management from 1988 to 1990 in
Germany, and got EMBA of China Europe International Business School from
1998 to 2000.
Mr. Oku has been engaged in venture capital
business since 2003 and led the creation and investment activities of
several funds in Japan, Singapore, and China. Serving as a board observer
and director at several portfolio companies, he is actively involved in
several investments in health care and internet sectors in China. Mr. Oku
graduated from Tokyo University of Agriculture and Technology with a M.E. in
biotechnology and life science.
Mr. Albert Liou serves as the Chairman of Fidelitas International Corporation, engaging in the investment of biotech medical equipment industry. Meanwhile he serves as the Chairman of ARDIC Instruments Co., focusing on pipeline of analytical instruments for educational, research, and industrial applications in nanotechnology. He also serves as Vice President of PAREXEL International, a leading global bio/pharmaceutical service organization, with main duties focusing on client relationships, business development and strategic initiatives in 13 countries in the Asia Pacific region including Taiwan, China, Japan, Korea, Singapore, and India etc. Mr. Liou has over 25 years of clinical research experience, of which 11 years were spent in the United States and 14 years in Asia. Mr. Liou received a B.S. in Mathematics from Fu-Jen University in Taiwan, a M.S. in Applied Mathematics: Computer Science from Minnesota State University, and a M.S. in Statistics from Iowa State University.
Mr. Haibo Wang, President and CEO of Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (FDZJ), where he oversees all the company's businesses and divisions. He is also the Chairman of FDZJ's Board of Directors. Prior to FDZJ, Mr. Wang served as the supervisor of Pudong Productivity Promotion Center and Associate Professor of Fudan University; meanwhile, he worked for Zhejiang Shenghua Biok Biology Co. Ltd., a listed company in the PRC, serving as the chief technology officer. He presided over the New Drug for R&D and development, including Avermectin, Maduramicin and Ivermectin. Now, he serves as the expert of National Significant Creation of new drugs.
Wilma Chyou-Jui Wei
Ms. Wilma Wei received her MBA from University of Washington in Seattle in 1980’s. Her career started from financial industry with experiences in cross border M&A, fund raising and structured finance. She was CFO of an electronic company for 10 years and she is now in charge of strategic investment in one of the reputable electronic companies in Taiwan.
RuiPing Dong, M.D.,Ph.D.
Senior Advisor to the Board. Dr. Dong joined Sundia from Merck, where he was a senior Vice President & Head of Emerging Markets R&D, responsible for overseeing Research & Development activities within Emerging Markets, building Emerging Markets Research & Development organization, and working with Commercial and manufacture divisions to lead overall Emerging markets strategy and execution. Prior to Merck, Dr. Dong was VP of Global Clinical Development and Medical Affairs at Bristol-Myers Squibb from 2004-2010. Dr. Dong also had 6 years working experience at AstraZeneca US and Japan from 1999 for oncology and pharmacology development. Dr Dong earned his M.D. from Jiangxi Medical School in China, and his Ph.D. from Kyushu University Medical School in Japan. Before he joined the pharmaceutical industry, he worked as a Research Fellow at the Dana-Farber Cancer Institute at Harvard Medical School.
Copyright© 2004-2010 Sundia MediTech Company, LTD. All rights reserved 沪ICP备 08100154号